HK1095743A1 - Ccn1 compositions and methods ccn1 - Google Patents

Ccn1 compositions and methods ccn1

Info

Publication number
HK1095743A1
HK1095743A1 HK07102927.7A HK07102927A HK1095743A1 HK 1095743 A1 HK1095743 A1 HK 1095743A1 HK 07102927 A HK07102927 A HK 07102927A HK 1095743 A1 HK1095743 A1 HK 1095743A1
Authority
HK
Hong Kong
Prior art keywords
ccn1
compositions
methods
methods ccn1
ccn1 compositions
Prior art date
Application number
HK07102927.7A
Inventor
Lester F Lau
Original Assignee
Munin Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Munin Corp filed Critical Munin Corp
Publication of HK1095743A1 publication Critical patent/HK1095743A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
HK07102927.7A 2003-06-20 2007-03-19 Ccn1 compositions and methods ccn1 HK1095743A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48016103P 2003-06-20 2003-06-20
PCT/US2004/019766 WO2005040191A2 (en) 2003-06-20 2004-06-21 Ccn1 compositions and methods

Publications (1)

Publication Number Publication Date
HK1095743A1 true HK1095743A1 (en) 2007-05-18

Family

ID=34519960

Family Applications (1)

Application Number Title Priority Date Filing Date
HK07102927.7A HK1095743A1 (en) 2003-06-20 2007-03-19 Ccn1 compositions and methods ccn1

Country Status (5)

Country Link
EP (1) EP1636251A4 (en)
CN (1) CN1835763B (en)
HK (1) HK1095743A1 (en)
TW (1) TWI356097B (en)
WO (1) WO2005040191A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2022511A1 (en) 2007-08-06 2009-02-11 Corlife GbR Bioactive coating for an implantable device or bioprosthesis
CA2712891A1 (en) 2008-01-30 2009-08-06 Corning Incorporated Synthetic surfaces for culturing stem cell derived cardiomyocytes
SG188096A1 (en) 2008-01-30 2013-03-28 Geron Corp Synthetic surfaces for culturing stem cell derived oligodendrocyte progenitor cells
TW201102086A (en) 2009-06-04 2011-01-16 Hoffmann La Roche Antibodies against human CCN1 and uses thereof
US20110183418A1 (en) * 2009-07-29 2011-07-28 Arthur Winston Martin Peptide-Polymer Cell Culture Articles and Methods of Making
CN104749371B (en) * 2013-12-30 2016-09-28 神州细胞工程有限公司 People's nephroblastoma overepressed gene encoding proteins enzyme linked immunological kit
CN105396136B (en) * 2015-11-23 2018-10-30 上海交通大学医学院附属第九人民医院 CCN1（Cyr61）Application in treatment skin injury and atrophoderma relevant disease
CN107505462A (en) * 2017-08-14 2017-12-22 上海市同仁医院 A kind of Cyr61 protein detection kits and its application method
CN107312864B (en) * 2017-08-14 2021-03-05 中国医学科学院北京协和医院 WISP3 gene mutation for PPD auxiliary diagnosis and application thereof
CN112118857A (en) * 2018-05-17 2020-12-22 株式会社橄榄生物科技 Pharmaceutical composition for preventing or treating retinal diseases comprising CCN5 as an active ingredient
CN114324526B (en) * 2021-12-27 2023-06-27 青岛农业大学 Biosensor for detecting prostate specific antigen in human serum and preparation method and application thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1071954A (en) * 1992-11-20 1993-05-12 沈阳市胸科医院 Method for pretreatment of specimen used in examining tubercle bacillus by polyase chain reaction
US6413735B1 (en) * 1996-03-15 2002-07-02 Munin Corporation Method of screening for a modulator of angiogenesis
DE60128066T2 (en) * 2000-01-31 2007-12-27 Munin Corporation, Chicago HUMANES CYR61

Also Published As

Publication number Publication date
CN1835763A (en) 2006-09-20
TWI356097B (en) 2012-01-11
EP1636251A2 (en) 2006-03-22
WO2005040191A3 (en) 2006-03-23
TW200513531A (en) 2005-04-16
EP1636251A4 (en) 2009-07-29
WO2005040191A2 (en) 2005-05-06
CN1835763B (en) 2011-04-20

Similar Documents

Publication Publication Date Title
AP2089A (en) Compositions and methods for combination antiviraltherapy
GB0411940D0 (en) Methods and compositions
EP1701725A4 (en) Methods and compositions
EP1619947A4 (en) Antibacterial methods and compositions
ZA200602885B (en) Antimicrobial compositions and methods
HK1095743A1 (en) Ccn1 compositions and methods ccn1
EP1646382A4 (en) Compounds, compositions and methods
EP1692112A4 (en) Compounds, compositions, and methods
EP1692131A4 (en) Methods and compositions for slowing aging
IL219406A0 (en) Antiloading compositions and methods of selecting same
GB0305941D0 (en) Composition
AU2003256805A8 (en) Compounds compositions and methods
GB0302738D0 (en) Composition
TWI348479B (en) Impact-modified compositions and method
EP1684771A4 (en) Composition and method
GB0303609D0 (en) Novel therapeutic method and compositions
EP1675834A4 (en) Compounds, compositions, and methods
EP1594849A4 (en) Compounds, compositions, and methods
EP1680420A4 (en) Compounds, compositions, and methods
EP1620092A4 (en) Compounds, compositions, and methods
EP1608970A4 (en) Ccn3 compositions and methods
EP1706111A4 (en) Compounds, compositions and methods
GB0327050D0 (en) Therapeutic methods compositions and uses
EP1622878A4 (en) Compounds, compositions and methods
GB0325942D0 (en) Compositions and uses thereof

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20220621